The goals of the 39 members of the Developmental Therapeutics and Clinical Trials Program are to conduct laboratory studies that identify strategies for new and more effective therapy for cancer and then to test those strategies in clinical trials.
Our specific aims are to improve treatment: 1) by gaining a better understanding of mechanisms of drug cytotoxicity and resistance; 2) by identify drugs that activate new cellular pathways of cytotoxicity; 3) by development complementary modes of treatment, including and radiation; and 4) by conducting phase I and II clinical trials that include pharmacokinetics and pharmacodynamics as well as measures of response using cellular and molecular surrogates and functional imaging. The Program encompasses laboratory development of new therapeutic strategies for solid tumors and leukemia and clinical therapeutic studies. Major areas of research are novel and conventional chemotherapy, which includes alkylating agents, platinum compounds, topoisomerase inhibitors, anti-metabolites, retinoids, and photosensitizers; immunotherapy, which includes peptide vaccines, peptide pulsed dendritic cells, and DNA-based vaccines as well as humanized monoclonal antibodies and monoclonal antibody/cytokine fusion proteins; anti-angiogenesis therapy targeting endothelial cell integrins, matrix metalloproteinases, and proteolyzed collagen; and gene therapy, which modifies leukemia cells rendering them more immunogenic and which targets retroviral vectors to tumors and tumor vasculature. Considerable efforts are focusing on developing strategies for treating minimal residual disease with retinoids, immunotherapy, and anti-angiogenesis therapies that are not affected by mechanisms by which cancer cells become resistant to chemotherapy and irradiation. Preclinical basic and translational laboratory studies are (CHLA) Research Institute. Phase I and II studies are conducted at the USC/Norris Comprehensive Cancer Center Hospital, USC/LA County Hospital, and CHLA, and promising studies are expanded throughout the country as consortium and cooperative group studiers. The Program is supported by $6.6 million in total direct costs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-26S1
Application #
6504890
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-04-06
Project End
2001-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Liu, Jie; Liang, Gangning; Siegmund, Kimberly D et al. (2018) Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics 19:369
Park, Sungshim L; Patel, Yesha M; Loo, Lenora W M et al. (2018) Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 10:110
Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640
McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880

Showing the most recent 10 out of 842 publications